Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Has Consensus Target Price of $21.00

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have earned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $21.00.

AMRX has been the topic of several research reports. Barclays boosted their price target on Amneal Pharmaceuticals from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Thursday, September 17th. Oppenheimer began coverage on shares of Amneal Pharmaceuticals in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $27.00 target price on the stock. Leerink Partners started coverage on shares of Amneal Pharmaceuticals in a report on Wednesday, September 9th. They set an “outperform” rating and a $23.00 target price on the stock. UBS Group restated a “buy” rating on shares of Amneal Pharmaceuticals in a research report on Thursday. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $21.00 price target on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st.

Insider Buying and Selling

In related news, EVP Nikita Shah sold 146,403 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the sale, the executive vice president directly owned 253,390 shares in the company, valued at $4,436,858.90. This represents a 36.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director John Kiely sold 50,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $17.64, for a total value of $882,000.00. Following the transaction, the director directly owned 210,252 shares of the company’s stock, valued at approximately $3,708,845.28. This represents a 19.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 413,016 shares of company stock valued at $7,216,567 over the last 90 days. 17.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in AMRX. Dimensional Fund Advisors LP increased its position in shares of Amneal Pharmaceuticals by 1.5% during the first quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company’s stock worth $70,723,000 after buying an additional 81,546 shares during the period. Allspring Global Investments Holdings LLC raised its stake in Amneal Pharmaceuticals by 72.2% during the first quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock worth $32,405,000 after buying an additional 1,069,400 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Amneal Pharmaceuticals in the second quarter valued at $17,573,000. Principal Financial Group Inc. lifted its holdings in Amneal Pharmaceuticals by 527.9% in the first quarter. Principal Financial Group Inc. now owns 972,529 shares of the company’s stock valued at $12,089,000 after buying an additional 817,652 shares during the period. Finally, First Trust Advisors LP boosted its position in Amneal Pharmaceuticals by 18.3% during the first quarter. First Trust Advisors LP now owns 757,157 shares of the company’s stock valued at $9,411,000 after acquiring an additional 116,873 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Trading Up 1.1%

NASDAQ AMRX opened at $20.30 on Friday. The company has a market cap of $6.48 billion, a price-to-earnings ratio of 41.43, a price-to-earnings-growth ratio of 2.36 and a beta of 1.22. Amneal Pharmaceuticals has a twelve month low of $9.56 and a twelve month high of $21.17. The company has a quick ratio of 1.44, a current ratio of 2.20 and a debt-to-equity ratio of 77.65. The business’s fifty day moving average is $18.31 and its 200 day moving average is $15.65.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. The business had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, sell-side analysts expect that Amneal Pharmaceuticals will post 0.95 EPS for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a global pharmaceutical company that develops, manufactures and markets a broad portfolio of generic and specialty medicines. The company focuses on complex and difficult-to-manufacture products, including injectables, biosimilars, ophthalmic medicines, respiratory treatments, oncology products, transdermal formulations and other dosage forms.

Amneal also operates a specialty pharmaceutical business focused on branded products in areas such as central nervous system disorders, endocrinology and other therapeutic categories.